A multicentre case control study on complicated coeliac disease: two different patterns of natural history, two different prognoses

Federico Biagi12*, Alessandra Marchese12, Francesca Ferretti12, Rachele Cicciocoppo12, Annalisa Schiepatti12, Umberto Volta1, Giacomo Caio1, Carolina Ciacchi2, Fabiana Zingone2, Anna D’Odorico3, Antonio Carroccio4, Giuseppe Ambrosiano5, Pasquale Mansueto5, Antonio Gasbarrini6, Anna Chiara Piscaglia6, Alida Andrealli7, Marco Astegiano7, Sergio Segato8, Matteo Neri9, Alberto Meggio10, Giovanni de Pretis10, Italo De Vitis11, Paolo Gobbi12 and Gino Roberto Corazza12

Abstract

**Background:** Coeliac disease is a common enteropathy characterized by an increased mortality mainly due to its complications. The natural history of complicated coeliac disease is characterised by two different types of course: patients with a new diagnosis of coeliac disease that do not improve despite a strict gluten-free diet (type A cases) and previously diagnosed coeliac patients that initially improved on a gluten-free diet but then relapsed despite a strict diet (type B cases). Our aim was to study the prognosis and survival of A and B cases.

**Methods:** Clinical and laboratory data from coeliac patients who later developed complications (A and B cases) and sex- and age-matched coeliac patients who normally responded to a gluten-free diet (controls) were collected among 11 Italian centres.

**Results:** 87 cases and 136 controls were enrolled. Complications tended to occur rapidly after the diagnosis of coeliac disease and cumulative survival dropped in the first months after diagnosis of complicated coeliac disease. Thirty-seven cases died (30/59 in group A, 7/28 in group B). Type B cases presented an increased survival rate compared to A cases.

**Conclusions:** Complicated coeliac disease is an extremely serious condition with a high mortality and a short survival. Survival depends on the type of natural history.

**Keyword:** Celiac disease, Complications, EATL, Prognosis, Glutens, Gluten-free diet

Background

Coeliac disease (CD), a chronic gluten-induced enteropathy, is common in western populations [1]. Although its prognosis is excellent in the great majority of cases, some of these patients may develop serious complications, such as refractory CD type 1 (RCD1), refractory CD type 2 (RCD2), ulcerative jejuno-ileitis (UJI), enteropathy associated T cell lymphoma (EATL), abdominal B cell lymphoma (ABL), small bowel carcinoma (SBC) and collagenous sprue (CS) [2-6]. Since treatment is hardly effective [7], they drastically reduce the prognosis of these patients [2]. In particular, five-year survival is between 80% and 96% in patients with RCD1, between 40% and 58% in patients with RCD2 and drops to less than 20% in patients with CD complicated by EATL [8-13]. These conditions have traditionally been considered the major complications of CD [14]. Moreover, since most of them share a common pathogenetic link [15], it is certainly possible to consider them altogether as complicated CD (CCD).

There are various factors correlated with the risk of developing CD complications. It has been known for some time that the main risk factor is poor compliance with a gluten-free diet (GFD) and, in the last few years, it has emerged that the clinical form of CD at diagnosis...
(classic/major, non-classic/minor, asymptomatic/silent [16]),
the diagnostic delay of CD, age at diagnosis of CD, and
homozygosity for HLA-DQ2 also correlate with the
risk of developing complications and thus with mortal-
ity [17–23]. Despite this additional knowledge, there
are still many obscure aspects.

The natural history of CCD has not yet been the subject
of specifically focussed studies. According to our experi-
ence, there are two different ways in which CCD can de-
velop clinically [24]. In some patients, the complication
of CD is diagnosed shortly after the diagnosis of CD itself
and the introduction of a strict GFD does not result in a
significant clinical improvement (for the purpose of
this paper we define these patients as “type A cases”).
Conversely, in other patients the diagnosis of CD is
made after a period of time during which the introduction
of a strict GFD is followed by a remission of the symptoms
that had led to the initial diagnosis of CD. Subsequently,
however, the reappearance of malabsorption, abdominal
pain, fever, or anaemia arouses the suspicion that a compi-
lcated form of CD is developing (“type B cases”). The preva-
ience and, above all, the prognosis of these two different
forms of onset of CCD have not yet been ascertained.

The aim of this study was to investigate the natural
history of CCD and to clarify its evolution and prognosis.

Patients and methods
Design of the study
To collect a sufficient number of patients, we organised
a retrospective multicenter case–control study based on
collection of clinical and laboratory data.

Cases and controls
Cases were recruited among adult coeliac patients
(age > 18 years), who, between 1990 and 2010, were
diagnosed with any of the following complications:
RCD1, RCD2, UJI, EATL, ABL, SBC, CS. Diagnoses of
EATL, ABL, SBC, and CS were based on morphological
criteria; diagnosis of RCD2 was based on a flat duodenal
mucosa not responding to 12 months on a GFD and evi-
dence of an aberrant intraepithelial lymphocyte population
and/or gamma-chain T-cell monoclonal rearrangement;
diagnosis of RCD1 was based on a flat duodenal mucosa
not responding to 12 months on a GFD but without the
diagnostic criteria for RCD2; diagnosis of UJI was based
on the demonstration of small bowel ulcers but without
the diagnostic criteria for EATL and RCD2 [3,9–12].
Cases were divided into types A and B according to the
type of natural history (see introduction). Other causes
of villous atrophy or clinically nonresponsive CD were
excluded [25,26].

Controls were recruited among adult patients (age >
18 years) found to be affected by CD on the basis of a
flat duodenal biopsy and positive endomysial/tissue
transglutaminase antibodies while on a gluten-containing
diet. They all clinically responded to a GFD and none of
them developed any of the above mentioned complications.
Two cases, or at least one, were matched to cases by gen-
der, age at diagnosis of CD (±5 years), year of first observa-
tion by the cooperating centre and length of follow-up.

Data collection
Date of birth, gender, date of diagnosis of CD, pattern of clinical
presentation of CD (classic, non classic, asymptomatic)
[16], adherence to a GFD evaluated by means of a dietary
interview, clinical response to a GFD, date of diagnosis
of CCD, type of complication, date and cause of death
(if the subject is still alive, date of the last time he/she was
seen in the clinic) are the very simple clinical data we col-
lected for each case and each control. Haemoglobin, RDW,
albumin, Na+, K+, Ca++, total cholesterol, triglycerides, glu-
cose, ESR, and CRP, at the time of diagnosis of CD, are the
laboratory tests we evaluated in cases and controls.

Statistics
The data obtained were analysed by means of descriptive
statistics, Student’s T test, and Mann–Whitney test where
appropriate. To study the survival over time of patients
with CCD we calculated the cumulative probability curve
by means of the Kaplan-Meier method. The complication-
free survival was calculated from the date of diagnosis
of CD to that of diagnosis of complication, whereas the sur-
vival of the CCD patients were calculated from the date
of diagnosis of complication to that of last known vital
status. The logrank analysis, performed according to the
Mantel-Cox method, and evaluated the presence of any
differences between the curves obtained [27,28].

The study protocol conforms to the ethical guidelines
of the 1975 Declaration of Helsinki (6th revision, 2008)
as reflected in a priori approval by the institution’s hu-
man research committee (Fondazione IRCCS Policlinico
San Matteo).

Results
Clinical study
Eleven Italian centres, distributed throughout the country,
took part in the study, allowing us to collect the clinical
data of 87 cases (55 females, mean age at diagnosis of CD
51.2 ± 14.3 years, median follow-up from the diagnosis of
CD 6.4 years, range 0.1-30.3) and 136 controls (89 females,
49.2 ± 13.3 years). Twenty of them were affected by RCD1,
3 by RCD2, 17 UJI, 17 EATL, 6 ABL, 16 SBC, and 1 CS. In
seven patients with RCD, the available data did not make it
possible to distinguish between RCD1 and RCD2 (RCDX).

Table 1 shows the main clinical results. As expected,
clinical type of CD, adherence to a GFD and mortality
were significantly different in the two groups. Figure 1
shows the Kaplan Meier curve calculated on the basis
of the complication-free time. Although most cases developed the complication soon after the diagnosis of CD, there is no limit beyond which the complications of CD no longer develop.

Table 2 show the clinical data of the cases divided according to the type of natural history. In 59 cases (68%) the complication arose without GFD, introduced after the initial diagnosis of CD based on flat duodenal biopsy, positive coeliac antibodies and/or coeliac HLA, having led to a considerable improvement in symptoms (type A cases). EATL affected 16 patients, UJI 13, SBC 12, RCD1 8, RCD2 1, RCDX 4, and ABL 5. Only 28 of them (47%) were still alive at the time when these data were collected; the other cases all died because of the condition complicating CD.

In the last 28 cases (32%), a diagnosis of CCD was reached after a period of time (median 5.0 years, 25th-75th percentile 3.3-8.1 years) in which the GFD had led to a remission of the malabsorption symptoms that had triggered the diagnosis of CD (cases type B). RCD1 was diagnosed in 12 patients, RCD2 in 2, RCDX in 3, UJI in 4, SBC in 4, EATL, ABL, and CS in one patient each. Twenty-one out of 28 (75%) were still alive at the time these data were collected; the other cases all died because of the condition complicating CD.

Table 3 shows the main laboratory test results at the time of diagnosis of CD in cases and controls. Already at the time of diagnosis of CD, levels of haemoglobin, albumin, cholesterol and serum electrolytes were lower than in controls. Conversely, inflammatory markers were higher than in controls.

As far as possible differences between type A and type B cases are concerned, there was no difference between these two groups in any of the laboratory tests, apart from triglyceride levels that were higher in type A cases (133.5 mg/dL ± 74.8) than in type B cases (87.0 mg/dL ± 31.4).

Survival study

The mortality of this condition is extremely high, since only 50 out of the 87 cases (58%) were still alive when these data were collected. Figure 2 shows the cumulative survival of the 87 cases, starting from the time at which CCD was diagnosed. It can be observed that survival was drastically reduced in the first 6 months and continued to be reduced, albeit more slowly, up to 5 years after the diagnosis of CCD. Once this limit has been passed, the survival seems to stabilize.

Figure 3 shows the cumulative survival at 10 years according to the two different types of natural history. Type B cases presented an increased survival rate compared to type A cases (logrank, $p = 0.0006$).

Cumulative 10-year survival according to the histopathological subtype of CCD, analysed by means of Kaplan Meyer curves and subsequent logrank analysis, did not show any statistically significant differences (data not shown). It is, however, likely that this could be due to the fact that it was necessary to divide the cases into six subgroups, with an inevitable reduction of statistical power.

Discussion

This study investigates the natural history of CCD and provides both new results and confirmation of results already reported in the literature.

Although the complications of CD tend to develop just after the diagnosis of CD in most cases, these complications...
can also arise even after many years (Figure 1). This confirms the well-known importance of maintaining a regular clinical follow up in all celiac patients, especially those diagnosed in adulthood. Very interestingly, we demonstrated that on the basis of the initial response to a GFD it is possible to identify two different clinical forms of CCD and that these present substantial differences in terms of survival (Figure 3). In patients who develop a complication after remission of the symptoms that led to the initial diagnosis of CD (type B cases), the prognosis is better than in patients in whom the complication of CD developed without the initial symptoms ever going into remission (type A cases). To explain this finding, we noted that EATL, UJI, and SBC are more frequent among cases type A than cases type B. On the other hand, RCD1 is more frequent among cases type B. Thus, we could hypothesise that, in those celiac patients who developed complications very rapidly without GFD being able to induce any remission of the symptoms, a malignant complication had already been triggered when CD was diagnosed. The course of the disease was therefore much more aggressive. Finally, since nowadays there is no efficient treatment for these complications [7], this finding is unlikely to have an immediate, strong clinical impact. Nevertheless, it certainly helps in better understanding the clinical course of these conditions and in figuring out their prognoses.

As regards the different histopathological subtypes, we showed that RCD, UJI, and EATL, the complications well-known to share a common pathogenetic link [15], are definitively the most common complications (64/87, 73.5%), SBC and ABL occur in 18% and 7% of the cases respectively, and CS seems to be exceptionally rare. Having found that almost 75% of the cases share a common pathogenetic link and that the others are affected by abdominal malignancies certainly supports our choice of considering all the cases as affected by CCD. According to our data, survival in each of these subtypes does not appear to be significantly different. However, since the literature reports very different survival rates for each of these subtypes of complication [8-12], we believe that our result is due to the relatively limited size of our sample rather than to a really similar mortality.

Patients with RCD2 have already been found to be significantly more anaemic and hypoalbuminemic than patients with RCD1 [29]. Here we show that, already at the time of diagnosis of CD, not only haemoglobin and albumin but also electrolytes and cholesterol are significantly reduced in celiac patients who will later develop

| Table 2 Demographic and clinical data in the two forms of complicated coeliac disease: type A cases, celiac patients who never responded to a gluten-free diet, type B cases, celiac patients who initially responded to a gluten-free diet but then relapsed |
|----------------------------------------------------------|
| Cases type A | Cases type B | p     |
| Number (Females) | 59 (52) | 28 (23) | 0.02* |
| Age at diagnosis of CD (mean years ± sd) | 53 ± 14 | 54 ± 13 | NS** |
| Age at diagnosis of CCD (mean year ± sd) | 45/59 (83%) | 21/28 (75%) | NS* |
| Strict adherence to a gluten-free diet | 0.3 (0.1, 1.4) | 4.9 (3.3, 8.1) | <0.0001*** |
| Mortality | 30/59 (51%) | 7/28 (25%) | 0.03* |
| Years between diagnosis of CD and diagnosis of CCD: median (25th, 75th percentile) | 1.0 (0.1, 2.7) | 2.3 (0.3, 4.2) | NS*** |

*Chi* test, **t test, ***Mann–Whitney test, CD = coeliac disease; CCD = complicated coeliac disease; NS = not significant.

| Table 3 Mean ± standards deviation of the laboratory findings in patients with complicated coeliac disease (cases) and in celiac patients responding to a gluten-free diet (controls) |
|---------------------------------------------|
| Cases | Controls | p     |
| Haemoglobin (g/dL) | 11.0 ± 2.1 | 12.0 ± 2.2 | 0.0038 |
| RDW (%) | 13.8 ± 2.0 | 15.4 ± 6.9 | NS |
| ESR* (mm/h) | 20 (9–35) | 10 (6.8-15) | 0.005 |
| CRP* (mg/dL) | 0.9 (0.5-1.9) | 0.4 (0.3-0.5) | < 0.0001 |
| Albumin (g/dL) | 3.2 ± 0.7 | 4.1 ± 0.6 | 0.0001 |
| Na* (mEq/L) | 137.9 ± 6.9 | 141.1 ± 3.5 | 0.03 |
| K* (mEq/L) | 4.1 ± 0.7 | 4.3 ± 0.4 | 0.02 |
| Ca** (mEq/L) | 8.2 ± 1.2 | 9.2 ± 0.5 | < 0.0001 |
| Total cholesterol (mg/dL) | 145.9 ± 39.7 | 183.3 ± 45.7 | < 0.0001 |
| Triglycerides (mg/dL) | 110.3 ± 61.3 | 102.5 ± 46.7 | NS |
| Glucose (mg/dL) | 90.0 ± 14.8 | 89.7 ± 18.8 | NS |

*median and 25th-75th inter-quartile range.
complications compared to coeliac patients who will respond to a GFD. The reason why these nutritional parameters are lower in the first ones is likely to be linked to the fact that they are almost always affected by a classic/major form of CD (Table 1). On the other hand, the increased levels of ESR and CRP we found in some cases suggest that an increased systemic inflammatory response, likely to be linked to the onset of the complication, was already present at the time of diagnosis of CD.

Our study made it possible to confirm a series of results already present in the literature, and this is an obvious demonstration of the validity of all our results. In particular, we confirm that the complications of CD are burdened by a high rate of mortality and that death occurs soon after the diagnosis of the complication (Figure 2). We also confirmed that coeliac patients who do not adhere to a strict GFD, with symptoms of classic CD at the onset and with a diagnosis late in life are at greater risk of developing these complications [18].

This study also presents some problems, linked fundamentally to its retrospective and multicentre nature. The study is based on 87 cases who had been attending 11 different Italian centres over the last 15 years; 37 of them were already dead when the data were collected. Moreover, the diagnoses of the CCD subtypes were those made by the individual centres and it was not possible to bring them into line. While this is probably not a problem as regards the diagnosis of lymphoma and cancer of the small intestine, it is inevitable that it influenced the differential diagnosis between RCD1 and RCD2, a diagnosis that has only been possible for a few years and certainly not in all centres. This type of problem is, on the other hand, well known and already reported in the literature [5]. Moreover, in seven of our cases of RCD the available data did not make it possible to distinguish between type 1 and 2. Evaluation of the strictness of a GFD was also necessarily based on the clinical judgement of each centre, without it being possible to even out this evaluation. Finally, our median follow up was rather short (2.9 years). However, this was due to the rapid onset of most complications and to their severe prognosis.

These organisational problems could be resolved with a prospective study. This is, however, very difficult to organise. Since CCD develops in less than 1% of patients [4–6,8], then to enrol at least 100 patients with CCD we would have to diagnose at least 10 000 new adult patients with CD, follow them for several years before identifying those that will develop a complication and then study their clinical evolution and survival.

Conclusions

Our study reveals previously unrecognised, interesting and innovative aspects of CCD. While on one hand we have in fact confirmed a series of data already present in the literature, on the other we have identified two clinical subtypes of CCD distinguished on the basis of the initial clinical response to a GFD and on survival.

Abbreviations

CD: Coeliac disease; RCD1: Refractory CD type 1; RCD2: Refractory CD type 2; UJI: Ulcerative jejuno-ileitis; EATL: Enteropathy associated T cell lymphoma; ABL: Abdominal B cell lymphoma; SBC: Small bowel carcinoma; CS: Collagenous sprue; GFD: Gluten-free diet.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

FB planned the study and wrote the manuscript together with FF and GRC; AM, RC, AS, U/GC, CC, FZ, ADO, AC, GA, PM, AG, ACP, AA, MA, SS, MN, AM, GdP, and IDV took care of the patients and collected the data in the respective centres; FB, FF and PG performed the statistical analysis. All authors read and approved the final manuscript.

Acknowledgements

This project was supported by a grant from the Fondazione Celiachia “Studio di possibili fattori ambientali e sviluppo di nuove strategie terapeutiche nelle complicanze della malattia celiaca”. The founding source had no role. We are grateful to Susan West for reading and correcting the manuscript.

Author details

1 Coeliac Centre/Department of Clinical Medicine, St Orsola-Malpighi University Hospital, Bologna, Italy. 2 Department of Medicine and Surgery, Gastrointestinal Immune Diseases Centre, University of Salerno, Salerno, Italy. 3 Department of Surgical and Gastroenterological Sciences, University of Padua, Padua, Italy. 4 Ospedali Civili Riuniti di Sciacca, University of Palermo, Palermo, Italy. 5 Internal Medicine, University of Palermo, Palermo, Italy. 6 Department of Internal Medicine, Catholic University of Sacred Heart, Gemelli University Hospital, Rome, Italy. 7 Department of Gastro-Hepatology, AOI San Giovanni Battista Molinette, University of Turin, Turin, Italy. 8 Gastroenterology and Endoscopy Unit, Ospedale di Circolo di Varese, Fondazione Macchi, Turin, Italy. 9 Department of Internal Medicine, University “G D’Annunzio” of Chieti, Turin, Italy. 10 UO Multizionale di Gastroenterologia ed Endoscopia APS Trento, Rome, Italy. 11 Internal Medicine and...
Gastroenterology Unit, UCSC-CIC, Rome, Italy. 1. Coeliac Centre/First Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo, University of Pavia, P.le Golgi, 19, I-27100, Pavia, Italy.

Received: 3 January 2014 Accepted: 28 July 2014 Published: 7 August 2014

References

1. Biagi F, Klersy C, Balduzzi D, Corazza GR: Are we not over-estimating the prevalence of coeliac disease in the general population? Am J Med 2010, 129:557–561.

2. Biagi F, Corazza GR: Mortality in celiac disease. Nat Rev Gastroenterol Hepatol 2010, 7:158–162.

3. Biagi F, Lorenzini P, Corazza GR: Literature review on the clinical relationship between ulcerative jejunoileitis, coeliac disease, and enteropathy-associated T-cell. Scand J Gastroenterol 2000, 35:795–799.

4. Biagi F, Goebi P, Marchese A, Bonetti E, Zingone F, Ciacci C, Volta U, Caio G, Carroccio A, Ambrosiano G, Mansueto P, Corazza GR: Low incidence but poor prognosis of complicated coeliac disease: a retrospective multicentre study. Dig Liver Dis 2014, 46:227–30.

5. Malamut G, Cellier C: Is refractory celiac disease more severe in old Europe? Am J Gastroenterol 2011, 106:929–932.

6. West J: Celiac disease and its complications: a time traveller’s perspective. Gastroenterology 2009, 136:32–34.

7. Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA: American College of Gastroenterology: ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol 2013, 108:656–676.

8. Rosihan B, Leffler DA, Jamma S, Dennis M, Sheh S, Falchuk K, Najjarin R, Goldsmith J, Taris S, Schuppan D, Kelly CP: The incidence and clinical spectrum of refractory celiac disease in a north american referral center. Am J Gastroenterol 2011, 106:923–928.

9. Malamut G, Alchfan P, Verkame L, Lecomte T, Amiot A, Damotte D, Bouhnik Y, Colombo IF, Delchier JC, Allez M, Cozen J, Lavenige-Slove A, Meresse B, Tinquet L, Macintyre E, Radford-Weiss I, Hermine O, Brousse N, Cerf-Bensussan N, Cellier C: Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology 2009, 136:81–90.

10. Al-Toma A, Verbeeck WH, Hiditi M, von Blomberg BM, Mulder CJ: Survival in refractory celiac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut 2007, 56:1375–1378.

11. Daum S, Iczyszyn R, Schumann M, Wahnschaffe U, Ullrich R: Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy-associated T-cell lymphoma. Clin Gastroenterol Hepatol 2006, 4:315–319.

12. Howell WM, Leung ST, Jones DB, Nakshabendi I, Hall MA, Lanchbury JS, Ciclitira PJ, Wright DH: HLA-DRB1, −DQA, and −DQB polymorphism in celiac disease and enteropathy-associated T-cell lymphoma. Common features and additional risk factors for malignancy. Human Immunol 1995, 43:29–37.

13. Biagi F, Bianchi P, Vattio A, Marchese A, Trolta L, Badulli C, De Silvestri A, Martiretti M, Corazza GR: The influence of HLA-DQ2 and DQ8 on severity in celiac disease. J Clin Gastroenterol 2012, 46:45–50.

14. Corazza GR, Gisbertini G: Coeliac disease in adults. Bailliere’s Clin Gastroenterol 1995, 9:29–31.

15. Deffert DA, Dennis M, Tyer B, Kelly E, Schuppan D, Kelly CP: Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol 2007, 5:445–450.

16. Biagi F, Bianchi P, Zili A, Marchese A, Luinetti O, Lougari V, Peabani A, Villanacci V, Corazza GR: The significance of duodenal mucosal atrophy in patients with common variable immunodeficiency: a clinical and histopathologic study. Am J Clin Pathol 2012, 138:185–189.

17. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457–481.

18. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II Analysis and examples Br J Cancer 1977, 35:1–39.

19. Rubio-Tapia A, Malamut G, Leffler D, Niveloni S, Arguelles-Grande C, Verbeeck W, Murray JA, Kelly C, Bai J, Green P, Daum S, Mulder C, Cellier C: Clinical features and survival in refractory celiac disease: preliminary report from a multinational collaborative study. In Abstract book 14th International Coeliac Disease Symposium: 20–22 June 2011. Oslo: University of Oslo, Norway 2011:34.

Cite this article as: Biagi et al.: A multicentre case control study on complicated coeliac disease: two different patterns of natural history, two different prognoses. BMC Gastroenterology 2014 14:139.